This HTML5 document contains 134 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/guide-to-pharmacology/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/chebi/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/wikipedia/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n8http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/iuphar/
n29http://linked.opendata.cz/ontology/sukl/drug/
n30http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00679/identifier/drugbank/

Statements

Subject Item
n2:DB00679
rdf:type
n3:Drug
n3:description
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)
n3:dosage
n25:271B42DF-363D-11E5-9242-09173F13E4C5 n25:271B42E0-363D-11E5-9242-09173F13E4C5 n25:271B42E2-363D-11E5-9242-09173F13E4C5 n25:271B42E3-363D-11E5-9242-09173F13E4C5 n25:271B42E4-363D-11E5-9242-09173F13E4C5 n25:271B42E1-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
21-25 hours
n3:indication
For the treatment of schizophrenia and generalized anxiety disorder.
n3:manufacturer
n4:271B42CA-363D-11E5-9242-09173F13E4C5 n4:271B42CB-363D-11E5-9242-09173F13E4C5 n4:271B42C8-363D-11E5-9242-09173F13E4C5 n4:271B42C9-363D-11E5-9242-09173F13E4C5 n4:271B42CE-363D-11E5-9242-09173F13E4C5 n4:271B42CF-363D-11E5-9242-09173F13E4C5 n4:271B42CC-363D-11E5-9242-09173F13E4C5 n4:271B42CD-363D-11E5-9242-09173F13E4C5 n4:271B42D2-363D-11E5-9242-09173F13E4C5 n4:271B42D0-363D-11E5-9242-09173F13E4C5 n4:271B42D1-363D-11E5-9242-09173F13E4C5 n4:271B42C2-363D-11E5-9242-09173F13E4C5 n4:271B42C3-363D-11E5-9242-09173F13E4C5 n4:271B42C6-363D-11E5-9242-09173F13E4C5 n4:271B42C7-363D-11E5-9242-09173F13E4C5 n4:271B42C4-363D-11E5-9242-09173F13E4C5 n4:271B42C5-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00679 n13:DB00679
dcterms:title
Thioridazine
adms:identifier
n11:Thioridazine n14:5253 n15:DB00679 n16:9566 n17:100 n18:D00373 n19:100 n20:5452 n21:46509070 n22:0378-0612-01 n23:PA451666
n3:mechanismOfAction
Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
n3:packager
n4:271B42AE-363D-11E5-9242-09173F13E4C5 n4:271B42AF-363D-11E5-9242-09173F13E4C5 n4:271B42AC-363D-11E5-9242-09173F13E4C5 n4:271B42AD-363D-11E5-9242-09173F13E4C5 n4:271B42BE-363D-11E5-9242-09173F13E4C5 n4:271B42BF-363D-11E5-9242-09173F13E4C5 n4:271B42BC-363D-11E5-9242-09173F13E4C5 n4:271B42BD-363D-11E5-9242-09173F13E4C5 n4:271B42BA-363D-11E5-9242-09173F13E4C5 n4:271B42BB-363D-11E5-9242-09173F13E4C5 n4:271B42B8-363D-11E5-9242-09173F13E4C5 n4:271B42B9-363D-11E5-9242-09173F13E4C5 n4:271B42B6-363D-11E5-9242-09173F13E4C5 n4:271B42B7-363D-11E5-9242-09173F13E4C5 n4:271B42B4-363D-11E5-9242-09173F13E4C5 n4:271B42B5-363D-11E5-9242-09173F13E4C5 n4:271B42B2-363D-11E5-9242-09173F13E4C5 n4:271B42B3-363D-11E5-9242-09173F13E4C5 n4:271B42B0-363D-11E5-9242-09173F13E4C5 n4:271B42B1-363D-11E5-9242-09173F13E4C5 n4:271B42C0-363D-11E5-9242-09173F13E4C5 n4:271B42C1-363D-11E5-9242-09173F13E4C5
n3:synonym
2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine Mellaril-S Mellerette Sonapax Mallorol Thioridazinum Meleril Tioridazina Melleril 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine Malloryl Thioridazin Mellerets Mellaril 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine Orsanil
n3:toxicity
LD<sub>50</sub>=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
n3:proteinBinding
95%
n3:salt
n8:hasConcept
n9:M0021377
foaf:page
n27:thioridazine.htm n28:thioridazine.html
n3:IUPAC-Name
n5:271B42E9-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B42EF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B42EE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B42EB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B42EC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B42ED-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B42E7-363D-11E5-9242-09173F13E4C5 n5:271B42FE-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B42E5-363D-11E5-9242-09173F13E4C5 n5:271B42E8-363D-11E5-9242-09173F13E4C5 n5:271B4301-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B42E6-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B4302-363D-11E5-9242-09173F13E4C5
n29:hasATCCode
n30:N05AC02
n3:H-Bond-Acceptor-Count
n5:271B42F5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B42F6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B42F0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B42F1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B42F3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B42F2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B42F4-363D-11E5-9242-09173F13E4C5
n3:absorption
60%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
50-52-2
n3:category
n3:containedIn
n12:271B42DB-363D-11E5-9242-09173F13E4C5 n12:271B42DC-363D-11E5-9242-09173F13E4C5 n12:271B42DE-363D-11E5-9242-09173F13E4C5 n12:271B42D9-363D-11E5-9242-09173F13E4C5 n12:271B42DD-363D-11E5-9242-09173F13E4C5 n12:271B42D7-363D-11E5-9242-09173F13E4C5 n12:271B42D8-363D-11E5-9242-09173F13E4C5 n12:271B42D5-363D-11E5-9242-09173F13E4C5 n12:271B42D6-363D-11E5-9242-09173F13E4C5 n12:271B42D3-363D-11E5-9242-09173F13E4C5 n12:271B42D4-363D-11E5-9242-09173F13E4C5 n12:271B42DA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B42FA-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n5:271B4300-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B42FC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B42FD-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B42FF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B42F9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B42F8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B42FB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B42EA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B42F7-363D-11E5-9242-09173F13E4C5